Home/Filings/8-K/0001601830-26-000002
8-K//Current report

RECURSION PHARMACEUTICALS, INC. 8-K

Accession 0001601830-26-000002

$RXRXCIK 0001601830operating

Filed

Jan 11, 7:00 PM ET

Accepted

Jan 12, 8:21 AM ET

Size

5.5 MB

Accession

0001601830-26-000002

Research Summary

AI-generated summary of this filing

Updated

Recursion Pharmaceuticals Updates Investor Presentation for JP Morgan Conference

What Happened
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) filed a Form 8‑K on January 12, 2026 (Item 7.01) to disclose an updated investor presentation. The presentation, attached as Exhibit 99.1 to the filing, will be used at the JP Morgan Healthcare Conference and in meetings with investors. The filing is a Regulation FD disclosure providing public access to the company’s current investor materials.

Key Details

  • Filing date: January 12, 2026 (Form 8‑K, Items 7.01 and 9.01).
  • Exhibit: Investor Presentation dated January 12, 2026 (Exhibit 99.1) is attached to the filing.
  • Purpose: Presentation will be used at the JP Morgan Healthcare Conference and in investor meetings.
  • Scope: The 8‑K furnishes the presentation under Regulation FD; no other financial results, executive changes, or material agreements were reported in this filing.

Why It Matters
This filing alerts investors that Recursion has updated its public investor materials ahead of a major industry event (the JP Morgan Healthcare Conference). Investors and analysts should review Exhibit 99.1 to see the company’s latest strategic messaging, program updates, and presentation of priorities—because the slide deck represents the information Recursion is publicly sharing at upcoming investor engagements.

Documents

46 files

Issuer

RECURSION PHARMACEUTICALS, INC.

CIK 0001601830

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001601830

Filing Metadata

Form type
8-K
Filed
Jan 11, 7:00 PM ET
Accepted
Jan 12, 8:21 AM ET
Size
5.5 MB